Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA issues new approvals in NSCLC for Keytruda

Oct. 25, 2016

FDA places clinical hold on phase III program for Inovio's VGX-3100

Oct. 25, 2016

FDA clears IND for phase I trials of XMT-1522

Oct. 25, 2016

FDA puts partial clinical hold on enrollment in LADD trials

Oct. 25, 2016

VBI-1901 shows promising preclinical results

Oct. 24, 2016

Phase III study of denosumab in MM meets primary enpoint

Oct. 24, 2016

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Oct. 24, 2016

Advaxis begins part B of KEYNOTE-046 trial

Oct. 21, 2016

NBE Therapeutics and SOTIO to develop next-generation ADCs

Oct. 21, 2016

CFDA accepts CStone Pharmaceuticals' IND for anti-PD-L1 monoclonal antibody

Oct. 21, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...